AAPL   390.89 (+1.88%)
GOOGL   1,552.19 (+0.86%)
AMZN   3,236.87 (+1.15%)
NVDA   415.41 (-0.90%)
CGC   17.90 (+2.76%)
MU   50.68 (-0.04%)
TSLA   1,516.05 (-1.85%)
AMD   55.90 (+0.04%)
T   29.90 (-0.76%)
GILD   78.03 (+2.24%)
DIS   119.51 (+0.14%)
NFLX   552.08 (+0.61%)
BAC   24.23 (+0.87%)
AAPL   390.89 (+1.88%)
GOOGL   1,552.19 (+0.86%)
AMZN   3,236.87 (+1.15%)
NVDA   415.41 (-0.90%)
CGC   17.90 (+2.76%)
MU   50.68 (-0.04%)
TSLA   1,516.05 (-1.85%)
AMD   55.90 (+0.04%)
T   29.90 (-0.76%)
GILD   78.03 (+2.24%)
DIS   119.51 (+0.14%)
NFLX   552.08 (+0.61%)
BAC   24.23 (+0.87%)
AAPL   390.89 (+1.88%)
GOOGL   1,552.19 (+0.86%)
AMZN   3,236.87 (+1.15%)
NVDA   415.41 (-0.90%)
CGC   17.90 (+2.76%)
MU   50.68 (-0.04%)
TSLA   1,516.05 (-1.85%)
AMD   55.90 (+0.04%)
T   29.90 (-0.76%)
GILD   78.03 (+2.24%)
DIS   119.51 (+0.14%)
NFLX   552.08 (+0.61%)
BAC   24.23 (+0.87%)
AAPL   390.89 (+1.88%)
GOOGL   1,552.19 (+0.86%)
AMZN   3,236.87 (+1.15%)
NVDA   415.41 (-0.90%)
CGC   17.90 (+2.76%)
MU   50.68 (-0.04%)
TSLA   1,516.05 (-1.85%)
AMD   55.90 (+0.04%)
T   29.90 (-0.76%)
GILD   78.03 (+2.24%)
DIS   119.51 (+0.14%)
NFLX   552.08 (+0.61%)
BAC   24.23 (+0.87%)
Log in

NASDAQ:ETONEton Pharmaceuticals Stock Price, Forecast & News

$5.10
+0.05 (+0.99 %)
(As of 07/13/2020 02:15 PM ET)
Add
Compare
Today's Range
$4.89
Now: $5.10
$5.33
50-Day Range
$4.57
MA: $5.33
$6.09
52-Week Range
$2.50
Now: $5.10
$9.07
Volume8,986 shs
Average Volume224,938 shs
Market Capitalization$106.69 million
P/E RatioN/A
Dividend YieldN/A
Beta1.21
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-202 and ET-203, which are injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101, ET-102, and ET-104, which are oral liquid product candidates for neurological indications; and CT-100, a synthetic corticotropin therapeutic candidate for rheumatoid arthritis. It also develops DS-300, an injectable nutrition product candidate for neonates; DS-200, an injectable nutrition product for use as a supplement to intravenous solutions; and DS-100, an injectable nerve block for the relief of intractable pain. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.31 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ETON
CUSIPN/A
CIKN/A
Phone847-787-7361

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$460,000.00
Book Value$0.59 per share

Profitability

Net Income$-18,320,000.00

Miscellaneous

Employees15
Market Cap$106.69 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive ETON News and Ratings via Email

Sign-up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter.

Eton Pharmaceuticals (NASDAQ:ETON) Frequently Asked Questions

How has Eton Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Eton Pharmaceuticals' stock was trading at $4.20 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ETON stock has increased by 21.4% and is now trading at $5.10. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Eton Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eton Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eton Pharmaceuticals.

When is Eton Pharmaceuticals' next earnings date?

Eton Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Eton Pharmaceuticals.

How were Eton Pharmaceuticals' earnings last quarter?

Eton Pharmaceuticals Inc (NASDAQ:ETON) released its quarterly earnings results on Thursday, May, 14th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.28. The company had revenue of $0.10 million for the quarter, compared to analysts' expectations of $1.62 million. View Eton Pharmaceuticals' earnings history.

What price target have analysts set for ETON?

3 Wall Street analysts have issued 12 month target prices for Eton Pharmaceuticals' shares. Their forecasts range from $10.00 to $18.00. On average, they anticipate Eton Pharmaceuticals' stock price to reach $14.00 in the next year. This suggests a possible upside of 174.5% from the stock's current price. View analysts' price targets for Eton Pharmaceuticals.

Has Eton Pharmaceuticals been receiving favorable news coverage?

News coverage about ETON stock has trended very negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Eton Pharmaceuticals earned a coverage optimism score of -3.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Eton Pharmaceuticals.

Are investors shorting Eton Pharmaceuticals?

Eton Pharmaceuticals saw a drop in short interest in the month of June. As of June 15th, there was short interest totaling 290,400 shares, a drop of 36.8% from the May 31st total of 459,200 shares. Based on an average daily trading volume, of 82,400 shares, the short-interest ratio is presently 3.5 days. Approximately 2.1% of the shares of the company are short sold. View Eton Pharmaceuticals' Current Options Chain.

Who are some of Eton Pharmaceuticals' key competitors?

What other stocks do shareholders of Eton Pharmaceuticals own?

Who are Eton Pharmaceuticals' key executives?

Eton Pharmaceuticals' management team includes the following people:
  • Mr. Sean E. Brynjelsen, Pres, CEO & Director (Age 47)
  • Mr. W. Wilson Troutman CPA, CFO, Treasurer & Sec. (Age 64)

When did Eton Pharmaceuticals IPO?

(ETON) raised $22 million in an initial public offering (IPO) on Wednesday, November 14th 2018. The company issued 3,600,000 shares at a price of $6.00 per share. National Securities Corporation acted as the underwriter for the IPO.

What is Eton Pharmaceuticals' stock symbol?

Eton Pharmaceuticals trades on the NASDAQ under the ticker symbol "ETON."

How do I buy shares of Eton Pharmaceuticals?

Shares of ETON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eton Pharmaceuticals' stock price today?

One share of ETON stock can currently be purchased for approximately $5.10.

How big of a company is Eton Pharmaceuticals?

Eton Pharmaceuticals has a market capitalization of $106.69 million and generates $460,000.00 in revenue each year. The company earns $-18,320,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Eton Pharmaceuticals employs 15 workers across the globe.

What is Eton Pharmaceuticals' official website?

The official website for Eton Pharmaceuticals is www.etonpharma.com.

How can I contact Eton Pharmaceuticals?

Eton Pharmaceuticals' mailing address is 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010. The company can be reached via phone at 847-787-7361 or via email at [email protected]

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.